Company Overview - Jincheng Pharmaceutical (SZ 300233) announced on November 14 that its wholly-owned subsidiary, Beijing Jincheng Taier Pharmaceutical Co., Ltd., received the Medical Device Registration Certificate from the Beijing Drug Administration for its product "Medical Gynecological Gel" [1] - As of the report date, Jincheng Pharmaceutical has a market capitalization of 6.9 billion yuan [1] Revenue Composition - For the year 2024, Jincheng Pharmaceutical's revenue will be entirely derived from the pharmaceutical manufacturing sector, with a 100.0% contribution from this industry [1]

Core Viewpoint - Jincheng Pharmaceutical (300233) announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received a medical device registration certificate for medical gynecological gel from the Beijing Drug Administration [1] Company Summary - Jincheng Pharmaceutical's subsidiary has successfully obtained regulatory approval for a new medical device, indicating progress in its product development and potential market expansion [1]

Core Insights - The company, Jincheng Pharmaceutical, announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received a Medical Device Registration Certificate from the Beijing Drug Administration for a medical gynecological gel [1] - The registration certificate is valid from November 11, 2025, to November 10, 2030, indicating a long-term approval for the product [1] - The product works by forming a protective gel membrane on the vaginal wall, providing physical isolation from external bacteria, which aids in the prevention of gynecological infectious diseases [1] - This certification enriches Jincheng Tail's gynecological product line and expands its product offerings in the female health sector [1]

证券代码：300233 证券简称：金城医药 公告编号：2025-078 特此公告。 山东金城医药集团股份有限公司董事会 2025 年 11 月 14 日 山东金城医药集团股份有限公司 关于子公司取得医疗器械注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司之全资子公司北京金城泰尔制药有限公司 （以下简称"金城泰尔"）于近日收到北京市药品监督管理局下发的《中华人民 共和国医疗器械注册证》（注册证编号：京械注准 20252180915）（以下简称"《注 册证》"），现将主要内容公告如下： 二、 对公司的影响及风险提示 医用妇科凝胶是由凝胶和阴道给药器两部分组成，通过在阴道壁形成一层保 护性凝胶膜，实现物理隔离外界细菌的效果，从而阻止病原微生物定植。该产品 通过构建阴道壁物理屏障，形成微生物入侵的防护层，辅助预防因细菌、病原微 生物定植引发的妇科感染性疾病（如阴道炎等），为女性阴道健康提供日常防护 或术后修复期的辅助保障。 上述《注册证》的取得丰富了金城泰尔的妇科产品线，拓展了女性健康领域 的产品布局，对公司发展具有积极意义 ...

Group 1 - The company, Jincheng Pharmaceutical, reported that as of October 31, 2025, the total number of shareholders is expected to be 26,613 [1]

Core Viewpoint - Jincheng Pharmaceutical (300233) announced on November 13 that its subsidiary, Jincheng Taier, produces and sells Oseltamivir phosphate raw materials, which are used for the treatment and prevention of H1N1 influenza [1] Group 1 - The company is involved in the production and sales of Oseltamivir phosphate, a key antiviral medication [1] - The end formulation products of Oseltamivir phosphate are specifically indicated for the treatment and prevention of H1N1 influenza [1]

Core Viewpoint - Jincheng Pharmaceutical announced the transfer of production technology and licensing rights for "Progesterone Vaginal Soft Capsules" to Haimeini (Shanghai) Pharmaceutical Technology Co., Ltd. for a total fee of 50 million RMB [2] Group 1 - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Taier Pharmaceutical Co., Ltd., is involved in the transaction [2] - The product being transferred is "Progesterone Vaginal Soft Capsules" (brand name: Langyigeng Baifen®), for which Jincheng Taier holds the drug approval number [2] - The total transaction fee, including tax, is set at 50 million RMB [2]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced the transfer of production technology and marketing rights for "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd. for a total fee of 50 million yuan, which aligns with Jincheng Tail's product development strategy and aims to optimize its product structure and asset efficiency [1][1][1] Group 1 - Jincheng Tail, a wholly-owned subsidiary of Jincheng Pharmaceutical, holds the drug approval number for "Progesterone Vaginal Soft Capsules" (brand name: Langyigengbaifen®) [1] - The total transaction fee for the transfer of rights is 50 million yuan, including tax [1] - The transfer is expected to enhance Jincheng Tail's asset operation efficiency and further optimize its asset structure [1]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced the transfer of production technology and marketing rights for "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd for a total fee of 50 million yuan, which aligns with Jincheng Tail's product development strategy and aims to optimize its product structure and asset efficiency [1] Group 1 - Jincheng Tail, a wholly-owned subsidiary of Jincheng Pharmaceutical, holds the drug approval number for "Progesterone Vaginal Soft Capsules" (brand name: Langyigengbaifen®) [1] - The total transaction fee for the transfer of rights is 50 million yuan, including tax [1] - The transfer is expected to enhance Jincheng Tail's asset operation efficiency and further optimize its asset structure [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., plans to transfer its rights to the production technology and marketing authorization of "Progesterone Vaginal Soft Capsules" to Haimerni (Shanghai) Pharmaceutical Technology Co., Ltd. for a total fee of RMB 50 million [1] Group 1 - The transfer involves the production technology and marketing rights of "Progesterone Vaginal Soft Capsules" (brand name: Langyigeng Baofen) [1] - The total transaction fee is RMB 50 million, which has been agreed upon by both parties after considering the actual value of the product rights and market conditions [1]